The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Open accessAbstract
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surgical resection is recognized worldwide as the preferred treatment for patients with early stage HCC, whereas liver transplantation is indicated in those with early stage disease who are not deemed suitable for resection7,22.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, regimens including immune-checkpoint inhibitors (ICIs) are currently adopted as first-line therapies in clinical guidelines7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, clinical decisions are based on clinical factors including, but not limited to, performance status, tumour burden, liver function and comorbidities7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Now the positive results of IMbrave 050 (ref. 12) have led to a revised management algorithm for patients with early stage HCC by incorporating adjuvant therapies in this disease setting7 (Fig. 4).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–338 of 338
Singal, A. G., Tiro, J. A., Murphy, C. C., Blackwell, J.-M., Kramer, J. R., Khan, A., Liu, Y., Zhang, S., Phillips, J. L., & Hernáez, R. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.049 · Cited by 140
Self-citationSchnitzbauer, A. A., Filmann, N., Adam, R. A., Bachellier, P., Bechstein, W. O., Becker, T., Bhoori, S., Bilbao, I., Brockmann, J. G., Burra, P., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004280 · Cited by 140 · cited 1×
“[257 ] Guidance 3-to-6-month period of observation ( Level 2, Strong Recommendation ). a. Patients with AFP > 1000 ng/ml must be downstaged to AFP < 500 ng/ml to be considered downstaged ( Level 2, Strong Recommendation ).”
Schoenberger, H., Chong, N., Fetzer, D. T., Rich, N. E., Yokoo, T., Khatri, G., Olivares, J., Parikh, N. D., Yopp, A. C., Marrero, J. A., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.012 · Cited by 139 · cited 1×
“[66] A single-center study found severe visualization limitations (LI-RADS visualization score C) are associated with lower sensitivity for early HCC detection, suggesting these patients may warrant other surveillance strategies, such as MRI.”
Self-citationLeerapun, A., Suravarapu, S. V., Bida, J. P., Clark, R. J., Sanders, E. L., Mettler, T. A., Stadheim, L. M., Aderca, I., Moser, C. D., Nagorney, D. M., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.005 · Cited by 138 · cited 1×
“74] Two well-studied biomarkers include the Lens culinaris lectin binding subfraction of the AFP, or AFP-L3%, which measures a subfraction of AFP, [75] and des gamma carboxy prothrombin (DCP), also called protein induced by vitamin K absence/antagonist-II (PIVKA-II), a variant of prothrombin that…”
Risk factors for HCC in contemporary cohorts of patients with cirrhosis
Kanwal, F., Khaderi, S. A., Singal, A. G., Marrero, J. A., Loo, N., Asrani, S. K., Amos, C. I., Thrift, A. P., Gu, X., Luster, M., et al. (2022) · Hepatology · doi:10.1002/hep.32434 · Cited by 134 · cited 1×
“…is present in over 80% of patients with HCC. [7] Patients with cirrhosis from any etiology typically have a ∼ 2% annual risk of developing HCC. [8] Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain the predominant etiologic risk factors in many parts of the world,…”
Self-citationTROISI, R. I., Berardi, G., Morise, Z., Cipriani, F., Ariizumi, S., Sposito, C., Panetta, V., Simonelli, I., Kim, S., Goh, B. K. P., et al. (2021) · British journal of surgery · doi:10.1093/bjs/znaa041 · Cited by 133 · cited 1×
“[185,186] Extended indications for resection criteria Although surgical resection for HCC is mainly limited to BCLC Stage 0/A HCC, data support the role of surgical resection in select patients with multifocal HCC beyond BCLC Stage A criteria (Figure 10).”
Zhang, X., Gao, Y., Chen, Z., Chen, M., Li, L., Wen, T., Xu, L., Wang, K., Chai, Z., Guo, W., et al. (2018) · Hepatology · doi:10.1002/hep.30490 · Cited by 131 · cited 1×
“Although most data for hepatic resection in PVTT comes from Asia, [189,190] limited available data from Western centers support the role of surgical resection in selected patients, [191,192] particularly in subsegmental (Vp1) and segmental (Vp2), in which meaningful long-term survival has been…”
Mazzaferro, V. (2015) · Hepatology · doi:10.1002/hep.28420 · Cited by 127 · cited 1×
“…associated with worse post-LT outcome, [230 – 232] observing tumor behavior after LRT may allow for a more refined selection of candidates for LT. [213,233] Although a recent UNOS national analysis suggested ablation or TARE as initial LRT may be associated with reduced waitlist dropout compared…”
Katsanos, K. H., Kitrou, P. M., Spiliοpoulos, S., Maroulis, I. C., Petsas, T. G., & Karnabatidis, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184597 · Cited by 127
Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance
Simmons, O. L., Feng, Y., Parikh, N. D., & Singal, A. G. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.07.029 · Cited by 127 · cited 1×
“[90] Organized surveillance programs 93] Several models of organized surveillance programs have been proposed to improve surveillance implementation.”
Self-citationZangneh, H. F., Wong, W. W. L., Sander, B., Bell, C. M., Mumtaz, K., Kowgier, M. E., van der Meer, A. J., Cleary, S. P., Janssen, H. L. A., Chan, K., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.12.018 · Cited by 127 · cited 1×
“[53] Patients with noncirrhotic NAFLD have posed a dilemma for surveillance programs because nearly one fourth of NAFLD-related HCC occurs in the absence of cirrhosis; however, these patients have a very low annual HCC incidence of 0.008 per 100 person-years, so surveillance is not cost-effective…”
InfluentialHepatocellular carcinoma and lifestyles
Saran, U., Humar, B., Kolly, P., & Dufour, J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.028 · Cited by 126 · cited 1×
“[23] Dietary exposure to aflatoxin B1 and aristolochic acid are known cofactors for HCC in patients with HBV infection.”
Cho, C. S., Gönen, M., Shia, J., Kattan, M. W., Klimstra, D. S., Jarnagin, W. R., D'Angelica, M. I., Blumgart, L. H., & DeMatteo, R. P. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.07.031 · Cited by 126 · cited 1×
“Although risk prediction models to stratify individualized risk of postsurgical resection have been proposed, [195,196] current evidence does not support a survival benefit of more frequent surveillance.”
Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma
Bhangui, P., Allard, M., Vibert, É., Cherqui, D., Pelletier, G., Cunha, A. S., Guettier, C., Duclos‐Vallée, J., Saliba, F., Bismuth, H., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001442 · Cited by 120 · cited 2×
“Numerous studies have reported equivalent post-LT graft and patient outcomes in patients undergoing salvage LT. [217,218] A large comparative analysis of primary LT ( n = 340) versus resection with intent for salvage LT ( n = 130) revealed superior OS in primary LT versus salvage LT; however, the…”
Improved Surveillance for Hepatocellular Carcinoma With a Primary Care–Oriented Clinical Reminder
Beste, L. A., Ioannou, G. N., Yang, Y. H., Chang, M. F., Ross, D. B., & Dominitz, J. A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.033 · Cited by 119 · cited 1×
“[91,94,95] The AASLD recommends use of these evidence-based interventions to increase surveillance utilization in clinical practice.”
Value of PET/CT in the Management of Primary Hepatobiliary Tumors, Part 2
Sacks, A., Peller, P. J., Surasi, D. S., Chatburn, L. T., Mercier, G., & Subramaniam, R. M. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.11.6995 · Cited by 118 · cited 1×
“[145] Similarly, routine staging with CT of the pelvis or technetium-99m methylene diphosphonate bone scans is not cost-effective but can be considered in patients with AFP > 1000 ng/ml, macrovascular invasion, or multifocal bilobar disease to assess for asymptomatic bone metastases.”
Ronot, M., Fouque, O., Esvan, M., Lebigot, J., Aubé, C., & Vilgrain, V. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.014 · Cited by 118
Goldaracena, N., Gorgen, A., Doyle, A. C., Hansen, B. E., Tomiyama, K., Zhang, W., Ghanekar, A., Lilly, L. B., Cattral, M. S., Galvin, Z., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.029 · Cited by 117 · cited 1×
“[222,223] 226] Because of the ongoing critical organ shortage and recent allocation changes, LDLT is increasing in the United States, with a recent analysis of OPTN data demonstrating excellent post-LT survival in the setting of LDLT for HCC. [ 227,228 ] Use of bridging therapy Given the mandatory…”
Cucchetti, A., Cescon, M., Golfieri, R., Piscaglia, F., Renzulli, M., Neri, F., Cappelli, A., Mazzotti, F., Mosconi, C., Colecchia, A., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.025 · Cited by 116
Kim, H., An, J., Park, J., Park, S., Lim, Y., & Lee, E. (2019) · Hepatology · doi:10.1002/hep.30330 · Cited by 114 · cited 1×
“[83] To potentially reduce cost, abbreviated MRI examination protocols with shorter in-scanner time are being tested and have achieved encouraging sensitivities and specificities of 80% – 90% and 91% – 98%, respectively, in small cohort studies.”
Zheng, J., Chou, J., Gönen, M., Vachharajani, N., Chapman, W., Majella-Doyle, M. B., Turcotte, S., Vandenbroucke-Menu, F., Lapointe, R., Buettner, S., et al. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002360 · Cited by 114 · cited 1×
“[220,221] As such, it can be argued that these same patients may also be at higher risk for developing posttransplant recurrence and thus likely to have failed a primary LT approach (either waitlist dropout or post-LT recurrence).”
Intention‐to‐treat survival benefit of liver transplantation in patients with hepatocellular cancer
Lai, Q., Vitale, A., Iesari, S., Finkenstedt, A., Mennini, G., Spoletini, G., Hoppe‐Lotichius, M., Vennarecci, G., Manzia, T. M., Nicolini, D., et al. (2017) · Hepatology · doi:10.1002/hep.29342 · Cited by 113 · cited 1×
“[229] Because tumor progression despite LRT is associated with worse post-LT outcome, [230 – 232] observing tumor behavior after LRT may allow for a more refined selection of candidates for LT. [213,233] Although a recent UNOS national analysis suggested ablation or TARE as initial LRT may be…”
Kardashian, A. A., Florman, S. S., Haydel, B., Ruiz, R. M., Klintmalm, G. B. G., Lee, D. D., Taner, C. B., Aucejo, F., Tevar, A. D., Humar, A., et al. (2020) · Hepatology · doi:10.1002/hep.31210 · Cited by 112 · cited 1×
“239] Additionally, recent multicenter prospective studies have further confirmed the feasibility of tumor downstaging as well as the clear survival benefit of downstaging.”
Self-citationTrevisani, F., Santi, V., Gramenzi, A., Nolfo, M. A. D., Poggio, P. D., Benvegnù, L., Rapaccini, G., Farinati, F., Zoli, M., Borzio, F., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01395.x · Cited by 109 · cited 1×
“[47] Therefore, patients with Child-Turcotte-Pugh C cirrhosis on the LT list should undergo regular surveillance because early-stage HCC can lead to higher priority on the transplant waitlist and larger tumor burden may pre-clude liver transplantation; however, surveillance should not be performed…”
Mehta, N. J., Dodge, J. L., Roberts, J. P., Hirose, R., & Yao, F. Y. (2018) · Hepatology · doi:10.1002/hep.30413 · Cited by 109 · cited 1×
“[249,250] As noted above, candidates with an AFP ≥ 1000 ng/ml in the United States are not eligible for MELD exception points until AFP decreases to below 500 ng/ml with LRT. Additional serum biomarker cutoffs associated with high-risk explant pathology and worse post-LT outcome include AFP-L3 ≥…”
Self-citationvan der Pol, C. B., McInnes, M. D. F., Salameh, J., Levis, B., Chernyak, V., Sirlin, C. B., Bashir, M. R., Allen, B. C., Burke, L. M. B., Choi, J., et al. (2021) · Radiology · doi:10.1148/radiol.2021211244 · Cited by 109 · cited 1×
“APHE and delayed washout are the characteristics most strongly associated with HCC. [113] LI-RADS criteria consider tumor size because accuracy for imaging techniques decreases in lesions 2 cm. [97,98,114] Therefore, for nodules ≥ 2 cm, APHE and one additional criteria (washout, enhancing…”
Qin, S., Chen, Z., Fang, W. J., Ren, Z., Xu, R., Ryoo, B., Meng, Z., Bai, Y., Chen, X., Liu, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.383 · Cited by 108
Chong, N., Schoenberger, H., Yekkaluri, S., Fetzer, D. T., Rich, N. E., Yokoo, T., Gopal, P., Manwaring, C., Quirk, L., & Singal, A. G. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16779 · Cited by 108 · cited 2×
“67] The incremental benefit of adding AFP has long been debated.”
Self-citationA multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma
Lin, N., Lin, Y., Xu, J., Liu, D., Li, D., Meng, H., Gallant, M. A., Kubota, N., Roy, D., Li, J. S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1918 · Cited by 108 · cited 1×
“[70,80] Although there are emerging data for computed tomography (CT) – and magnetic resonance imaging (MRI) – based surveillance, the AASLD does not recommend routine use of these modalities in at-risk patients.”
Plasma Des–γ–Carboxyprothrombin in the Early Stage of Hepatocellular Carcinoma
Tsai, S., Huang, G., Yang, P., Sheu, J., Sung, J., & Chen, D. (1990) · Hepatology · doi:10.1002/hep.1840110321 · Cited by 107
Fowler, K. J., Tang, A., Santillan, C., Bhargavan, M., Heiken, J. P., Jha, R. C., Weinreb, J. C., Hussain, H. K., Mitchell, D. G., Bashir, M. R., et al. (2017) · Radiology · doi:10.1148/radiol.2017170376 · Cited by 106 · cited 1×
“[122,123] – 125] Among LR-M cases, rim APHE suggests non-HCC malignancy.”
Kim, D. J., Clark, P. J., Heimbach, J. K., Rosen, C. B. B., Sánchez, W., Watt, K. D. S., & Charlton, M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12684 · Cited by 101
Self-citationGarin, É., Rolland, Y., Pracht, M., Sourd, S. L., Laffont, S., Mesbah, H., Haumont, L.-A., Lenoir, L., Rohou, T., Brun, V., et al. (2016) · Liver International · doi:10.1111/liv.13220 · Cited by 99 · cited 1×
“[303] In the DOSISPHERE-01 trial, patients with unresectable HCC randomized to the personalized dosimetry arm had significantly improved objective responses (76.6% vs. 22.2%), downstaging to surgical treatments (35% vs. 3.5”
InfluentialLee, I., Hung, Y., Liu, C., Lee, R., Su, C., Huo, T., Li, C., Chao, Y., Lin, H., Hou, M., et al. (2019) · Liver International · doi:10.1111/liv.14194 · Cited by 99
Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma
Gabr, A., Abouchaleh, N., Ali, R., Baker, T., Caicedo, J. C., Katariya, N., Abecassis, M. M., Riaz, A., Lewandowski, R. J., & Salem, R. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.06.027 · Cited by 98 · cited 1×
“[174] Transarterial radioembolization (TARE) with Yttrium-90 has recently been established as an acceptable treatment for solitary unresectable HCC, [175] and there are increasing data for its utilization to enhance FLR [176] and allow for surgical resection.”
Serenari, M., Han, K., Ravaioli, F., Kim, S. U., Cucchetti, A., Han, D. H., Odaldi, F., Ravaioli, M., Festi, D., Pinna, A. D., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.032 · Cited by 98 · cited 1×
“…including the MELD score or MELD including sodium (MELD-Na), ALBI score, [171] indocyanine green kinetics, [172] and liver stiffness measurement by transient elastography [173] are associated with risk of postresection hepatic decompensation and may also be used to refine patient selection.”
Tsilimigras, D. I., Mehta, R., Paredes, A. Z., Moris, D., Sahara, K., Bagante, F., Ratti, F., Marques, H. P., da Silva, S. G., Soubrane, O., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004346 · Cited by 98 · cited 1×
“[188] Resection of patients with HCC with macrovascular portal vein tumor thrombus (PVTT) is more controversial because these patients have higher risk of metastatic disease and are typically recommended to undergo systemic therapy.”
Qin, S., Chan, L. S., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.032 · Cited by 97 · cited 1×
“Three RCTs from Asia demonstrated superior survival with the combination of camrelizumab and rivoceranib versus sorafenib, [326] TACE plus lenvatinib versus lenvatinib [327] and noninferior survival of tislelizumab versus sorafenib [328] ; however, it is unclear if these therapies apply to patients…”
Ogasawara, S., Chiba, T., Ooka, Y., Kanogawa, N., Saito, T., Motoyama, T., Suzuki, E., Tawada, A., Kanai, F., & Yokosuka, O. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0237-3 · Cited by 95 · cited 1×
“334] Real-world data suggest well-selected patients with Child-Turcotte-Pugh B liver disease, particularly those with Child-Turcotte-Pugh B7 liver disease from cancer-related hyperbilirubinemia and hypoalbuminemia, can sometimes tolerate systemic therapies traditionally reserved for patients with…”
Tayob, N., Lok, A. S.-F., Do, K.-A., & Feng, Z. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.049 · Cited by 94 · cited 1×
“[100] The optimal recall strategy is unknown for patients with markedly elevated AFP levels (e.g., AFP ≥ 200 ng/ml) but without a liver mass on diagnostic abdominal imaging; however, repeat abdominal imaging with an alternative modality (e.g., multiphasic MRI if patient first underwent CT) and…”
Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies
Islam, M. M., Poly, T. N., Walther, B. A., Yang, H., & Li, Y. (2020) · Cancers · doi:10.3390/cancers12030671 · Cited by 92
Tommaso, L. D., Destro, A., Fabbris, V., Spagnuolo, G., Fracanzani, A. L., Fargion, S. R., Maggioni, M., Patriarca, C., Macchi, R. M., Quagliuolo, M., et al. (2011) · Hepatology · doi:10.1002/hep.24218 · Cited by 90 · cited 1×
“…of four markers (glypican 3 [GPC3], glutamine synthetase, heat shock protein 70 [HSP70], and clathrin heavy chain) is highly specific for HCC. [131,132] Additional staining can be considered to detect progenitor cell features (K19 and epithelial cellular adhesion molecule) or neovascularization…”
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Yoon, J. H., Lee, J. M., Lee, D. H., Joo, I., Jeon, J. H., Ahn, S. J., Kim, S.-T., Cho, E. J., Lee, J., Yu, S. J., et al. (2020) · Liver Cancer · doi:10.1159/000506834 · Cited by 83 · cited 1×
“[81,82] However, neither have been validated in cohorts of Western patients without HBV.”
Narasimman, M., Hernáez, R., Cerda, V., Lee, M., Sood, A., Yekkaluri, S., Khan, A., Quirk, L., Liu, Y., Kramer, J. R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000528 · Cited by 83
Self-citationSheta, E. S., El-Kalla, F., El-Gharib, M., Kobtan, A. A., Elhendawy, M., Abd-Elsalam, S. M., Mansour, L., & Amer, I. F. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000688 · Cited by 80
Sinha, J., Mehta, N. J., Dodge, J. L., Poltavskiy, E. A., Roberts, J. P., & Yao, F. Y. (2019) · Hepatology · doi:10.1002/hep.30570 · Cited by 78 · cited 1×
“However, liberalizing downstaging criteria results in a lower rate of successful downstaging and a higher rate of waitlist dropout [243] as well as inferior post-LT survival.”
Self-citationChébaro, A., Buc, E., Durin, T., Chiche, L., Brustia, R., Alexandre, D., Pruvot, F., Kitano, Y., Muscari, F., Lécolle, K., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005121 · Cited by 75 · cited 1×
“[177] Other emerging methods to augment the FLR and allow surgical resection, such as associating liver partition and portal vein ligation for staged hepatectomy [178,179] and liver venous deprivation with portal vein and hepatic vein embolization, [180] are under investigation.”
Kim, Y., An, C., Kim, S., & Kim, M. (2017) · European Radiology · doi:10.1007/s00330-017-5188-y · Cited by 74
Lee, D. D., Sapisochín, G., Mehta, N. J., Gorgen, A., Musto, K. R., Hajda, H., Yao, F. Y., Hodge, D. O., Carter, R. E., & Harnois, D. M. (2020) · Transplantation · doi:10.1097/tp.0000000000003117 · Cited by 74 · cited 1×
“[254 ] The optimal timing and duration of posttransplant surveillance is uncertain.”
Self-citationDynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma
Halazun, K. J., Rosenblatt, R. E., Mehta, N. J., Lai, Q., Hajifathalian, K., Gorgen, A., Brar, G., Sasaki, K., Doyle, M. B. M., Tabrizian, P., et al. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.0954 · Cited by 74 · cited 1×
“[249,250] As noted above, candidates with an AFP ≥ 1000 ng/ml in the United States are not eligible for MELD exception points until AFP decreases to below 500 ng/ml with LRT. Additional serum biomarker cutoffs associated with high-risk explant pathology and worse post-LT outcome include AFP-L3 ≥…”
Self-citationWang, Y.-Y., Xiang, B.-D., Ma, L., Zhong, J.-H., Ye, J.-Z., Wang, K., Xing, B.-C., & Li, L.-Q. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003803 · Cited by 72 · cited 1×
“…incorporating tumor size, extent of resection, and measures of liver dysfunction have been proposed to predict postresection outcomes, [164,167] most data support surgical resection of a single lesion in a patient with compensated cirrhosis without CSPH and an adequate FLR (typically >…”
Azoulay, D., Ramos, E., Casellas‐Robert, M., Salloum, C., Lladó, L., Nadler, R., Busquets, J., Caula-Freixa, C., Mils, K., López‐Ben, S., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100190 · Cited by 72
An, C., Li, W., Huang, Z., Yu, X., Han, Y.-Z., Liu, F., Wu, S., Yu, J., Liang, P., & Huang, J. (2021) · European Radiology · doi:10.1007/s00330-020-07571-5 · Cited by 72 · cited 1×
“[269] Thermal ablation yields OS and recurrence-free survival of 76% and ∼ 46%, respectively, at 3 years for unifocal HCC ≤ 3 cm. [263] 274] Use of CEUS after ablation to assess for any viable disease and enable retreatment as needed can optimize complete response.”
Tustumi, F., Ernani, L., Coelho, F. F., Bernardo, W. M., Junior, S. S., Krüger, J. A. P., Fonseca, G. M., Jeismann, V. B., Cecconello, I., & Herman, P. (2018) · HPB · doi:10.1016/j.hpb.2018.06.1798 · Cited by 71 · cited 1×
“[177] Other emerging methods to augment the FLR and allow surgical resection, such as associating liver partition and portal vein ligation for staged hepatectomy [178,179] and liver venous deprivation with portal vein and hepatic vein embolization, [180] are under investigation.”
Tsilimigras, D. I., Bagante, F., Moris, D., Merath, K., Paredes, A. Z., Sahara, K., Ratti, F., Marques, H. P., Soubrane, O., Lam, V. W. T., et al. (2019) · Surgery · doi:10.1016/j.surg.2019.08.010 · Cited by 70 · cited 1×
“From an oncologic perspective, tumor number, [162,163] anatomic location, presence of vascular invasion, and planned extent of hepatectomy [164,165] are important determinants of feasibility for surgical resection.”
Fujiwara, N., Kobayashi, M., Fobar, A. J., Hoshida, A., Marquez, C. A., Koneru, B., Panda, G., Taguri, M., Qian, T., Raman, I., et al. (2021) · Med · doi:10.1016/j.medj.2021.03.017 · Cited by 70
Self-citationAmponsah‐Dacosta, E. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i36.6025 · Cited by 70 · cited 1×
“[12,13] This age disparity persists in people who are HBV-infected and emigrate elsewhere, such that more than one third of persons from Africa who develop HCC are diagnosed before age 40 years.”
Multidisciplinary care for patients with HCC: a systematic review and meta-analysis
Dahan, K. S. E., Reczek, A., Daher, D., Rich, N. E., Yang, J. D., Hsiehchen, D., Zhu, H., Patel, M. S., Molano, M. D. P. B., Sanford, N. N., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000143 · Cited by 69
Self-citationPredicting recurrence patterns after resection of hepatocellular cancer
Lee, S. Y., Konstantinidis, I. T., Eaton, A. A., Gönen, M., Kingham, T. P., D'Angelica, M. I., Allen, P. J., Fong, Y., DeMatteo, R. P., & Jarnagin, W. R. (2014) · HPB · doi:10.1111/hpb.12311 · Cited by 69 · cited 1×
“[220,221] As such, it can be argued that these same patients may also be at higher risk for developing posttransplant recurrence and thus likely to have failed a primary LT approach (either waitlist dropout or post-LT recurrence).”
von Felden, J., García‐Lezana, T., Dogra, N., Gonzalez‐Kozlova, E., Ahsen, M. E., Craig, A. J., Gifford, S. M., Wunsch, B. H., Smith, J. T., Kim, S., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325036 · Cited by 68 · cited 1×
“[141] Alterations in ctDNA, ctDNA methylation profiles, [142] and extracellular RNA signatures from exosomes [143,144] have been explored in case-control studies for early detection and diagnosis.”
Self-citationManini, M. A., Sangiovanni, A., Fornari, F., Piscaglia, F., Biolato, M., Fanigliulo, L., Ravaldi, E., Grieco, A., & Colombo, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.006 · Cited by 67 · cited 1×
“[101,102] In these patients (Figure 6), arterial phase hyperenhancement (APHE) and washout on portal venous or delayed phases of contrast-enhanced multiphase CT or MRI are considered radiological hallmarks of HCC given high specificity and positive predictive value in lesions ≥ 1 cm in size.”
Yang, J. D., Altekruse, S. F., Nguyen, M. H., Gores, G. J., & Roberts, L. R. (2016) · Cancer · doi:10.1002/cncr.30246 · Cited by 67
Fetzer, D. T., Browning, T., Xi, Y., Yokoo, T., & Singal, A. G. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26735 · Cited by 67
Self-citationMehta, N. J., Sarkar, M., Dodge, J. L., Fidelman, N. A., Roberts, J. P., & Yao, F. Y. (2015) · Liver Transplantation · doi:10.1002/lt.24360 · Cited by 66 · cited 1×
“…AFP is r 20 ng/ml appear to have low risk of rapid progression; however, those with significant AFP elevation (e.g., > 100 ng/ml) are more likely to have rapid tumor growth and progress to beyond Milan criteria during an observation period [88,244] and therefore immediate LRT may be considered.”
Self-citationRich, N., Carr, C., Yopp, A., Marrero, J., & Singal, A. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.12.029 · Cited by 66 · cited 1×
“[5] In the United States, HCC incidence and mortality rates increased from 1970 to 2010, but incidence began to decrease in 2011, and mortality plateaued in 2013, with one study showing a subsequent ∼ 3% decrease per year.”
Self-citationIzumi, N., Hasegawa, K., Nishioka, Y., Takayama, T., Yamanaka, N., Kudo, M., Shimada, M., Inomata, M., Kaneko, S., Baba, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4002 · Cited by 66
de Haas, R. J., Lim, C., Bhangui, P., Salloum, C., Compagnon, P., Feray, C., Calderaro, J., Luciani, A., & Azoulay, D. (2018) · Hepatology · doi:10.1002/hep.29468 · Cited by 65 · cited 1×
“[219] A criticism of salvage LT strategies has been that less than 50% of patients with HCC who develop postresection recurrence are deemed candidates for salvage LT, primarily because of development of extrahepatic recurrences or intrahepatic recurrence beyond Milan criteria.”
AGA Clinical Practice Update on Palliative Care Management in Cirrhosis: Expert Review
Tandon, P., Walling, A. M., Patton, H. M., & Taddei, T. H. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.11.027 · Cited by 63 · cited 1×
“[337] Defining goals of care should be done early for these patients to facilitate shared decision-making and incorporate patients ’ personal values into treatment choices.”
Self-citationWang, M., Šanda, M., Comunale, M. A., Herrera, H., Swindell, C. S., Kono, Y., Singal, A. G., Marrero, J. B., Block, T. M., Goldman, R., et al. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0974 · Cited by 62 · cited 1×
“…Specificity 81% Multitarget algorithm [70] 2 Sensitivity 82% Specificity 87% GALAD [ 71 ] 2/3 Sensitivity 54 – 72% Specificity 90% Doylestown plus [72] 2/3 Sensitivity 90% Specificity 95% Turcotte-Pugh B or C cirrhosis, so this may be a population in which blood-based biomarkers are particularly…”
Self-citationBhurwal, A., Ratta, P., Yoshitake, S., Pioppo, L., Reja, D., Dellatore, P., & Rustgi, V. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-805 · Cited by 61 · cited 1×
“[38] Decaffeinated coffee appears to have similar benefits, although to a lesser magnitude.”
Chen, C., Yang, Y., Lin, M., Lee, C., Tsan, Y., Lai, M., Yang, H., Ho, W., & Chen, P. (2018) · International Journal of Cancer · doi:10.1002/ijc.31544 · Cited by 61
Wong, T. C.-L., Ng, K. K., Fung, J., Chan, A. C. Y., Cheung, T. T., Chok, K., Dai, J. W.-C., & Lo, C. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07206-0 · Cited by 61
Impact of a Single-Day Multidisciplinary Clinic on the Management of Patients with Liver Tumours
Zhang, J., Mavros, M. N., Cosgrove, D., Hirose, K., Herman, J. M., Smallwood–Massey, S., Kamel, I. R., Gurakar, A. O., Anders, R. A., Cameron, A. M., et al. (2013) · Current Oncology · doi:10.3747/co.20.1297 · Cited by 60
Role of US LI-RADS in the LI-RADS Algorithm
Rodgers, S. K., Fetzer, D. T., Gabriel, H. A., Seow, J. H.-S., Choi, H. H., Maturen, K. E., Wasnik, A. P., Morgan, T. A., Dahiya, N., O'Boyle, M. K., et al. (2019) · Radiographics · doi:10.1148/rg.2019180158 · Cited by 60 · cited 1×
“[96] Patients with a subcentimeter liver lesion on ultrasound (US-2) can be safely observed with repeat short-interval surveillance using ultrasound and AFP in 3-6 months given a low risk of HCC, suboptimal performance of CT or MRI to accurately diagnose HCC in lesions 1 cm, and expected tumor…”
Park, H. J., Kim, S. Y., Singal, A. G., Lee, S. J., Won, H. J., Byun, J. H., Choi, S. H., Yokoo, T., Kim, M., & Lim, Y. (2021) · Liver International · doi:10.1111/liv.15110 · Cited by 60 · cited 1×
“[84,85] Early data suggest MRI-based surveillance may have poorer performance in patients with Child-FIGURE Overall value of hepatocellular carcinoma (HCC) surveillance is determined by balance of benefits and harms.”
Self-citationContrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?
Bartolotta, T. V., Taibbi, A., Midiri, M., & Lagalla, R. (2019) · ULTRASONOGRAPHY · doi:10.14366/usg.18060 · Cited by 59 · cited 1×
“[110,111] CEUS can be used as a second-line modality in cases where MRI and CT are inconclusive, unavailable, or contraindicated, particularly when tumor biopsy is not feasible.”
Yang, Y., & Si, T. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0177 · Cited by 57 · cited 1×
“TARE can be used an accepted alternative intra-arterial therapy for intermediate-stage HCC. [ 299,300 ] In a small single-center RCT, Y90 glass microspheres produced significantly prolonged TTP, but similar OS, compared with TACE.”
El‐Serag, H. B., Kanwal, F., Feng, Z., Marrero, J. A., Khaderi, S. A., & Singal, A. G. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.049 · Cited by 55
Self-citationKwong, A. J., Ghaziani, T., Yao, F. Y., Sze, D. Y., Mannalithara, A., & Mehta, N. J. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.07.048 · Cited by 53 · cited 1×
“…for a more refined selection of candidates for LT. [213,233] Although a recent UNOS national analysis suggested ablation or TARE as initial LRT may be associated with reduced waitlist dropout compared with TACE, [234] currently no one type of LRT is recommended over another for bridging therapy.”
Self-citationLiu, C., Li, T. X., He, J., & Shao, H. (2020) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2020.19615 · Cited by 52
Govalan, R., Lauzon, M., Luu, M., Ahn, J. C., Kosari, K., Todo, T., Kim, I. K., Noureddin, M., Kuo, A., Ayoub, W. S., et al. (2021) · Liver Cancer · doi:10.1159/000515554 · Cited by 52 · cited 1×
“…most data for hepatic resection in PVTT comes from Asia, [189,190] limited available data from Western centers support the role of surgical resection in selected patients, [191,192] particularly in subsegmental (Vp1) and segmental (Vp2), in which meaningful long-term survival has been reported.”
Self-citationDynamic risk profiling of HCC recurrence after curative intent liver resection
Ivanics, T., Perez, C., Claasen, M. P. A. W., Patel, M. S., Morgenshtern, G., Erdman, L., Shwaartz, C. G., Rajendran, L., O'Kane, G. M., Hansen, B. E., et al. (2022) · Hepatology · doi:10.1002/hep.32411 · Cited by 51 · cited 1×
“[205] The Milan criteria (one lesion between 1 and 5 cm or two to three lesions between 1 and 3 cm) has been well established as the standard for optimal patient selection.”
Declining disease burden of HCC in the United States, 1992–2017: A population‐based analysis
Han, J., Wang, B., Liu, W., Wang, S., Chen, R., Chen, M., & Fu, Z. (2022) · Hepatology · doi:10.1002/hep.32355 · Cited by 50
Müllhaupt, B., Durand, F., Roskams, T., Dutkowski, P., & Heim, M. H. (2011) · Liver Transplantation · doi:10.1002/lt.22374 · Cited by 49
Mehta, N. J., Dodge, J. L., Hirose, R., Roberts, J. P., & Yao, F. Y. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15353 · Cited by 49 · cited 1×
“– 215] Since 2012, there have been stringent HCC imaging criteria to receive MELD exception points for LT. Arterial phase hyperenhancing lesions ≥ 2 cm were designated as Organ Procurement and Transplant Network (OPTN) class 5 (consistent with HCC) if they exhibited venous or delayed phase washout…”
Self-citationOverdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
Rich, N. E., & Singal, A. G. (2021) · Hepatology · doi:10.1002/hep.32284 · Cited by 48 · cited 1×
“[60,61] The overall value of HCC surveillance programs must balance surveillance benefits against potential physical, financial, and psychological harms (Figure 4).”
Self-citationFaccia, M., Garcovich, M., Ainora, M. E., Riccardi, L., Pompili, M., Gasbarrini, A., & Zocco, M. A. (2022) · Cancers · doi:10.3390/cancers14030481 · Cited by 48 · cited 1×
“[275] Adverse effects after thermal ablation are rare but can include pain, fever, bleeding, abscess, and pleural effusion.”
Amini, M., Looha, M. A., Zarean, E., & Pourhoseingholi, M. A. (2022) · BMC Public Health · doi:10.1186/s12889-022-12867-w · Cited by 48 · cited 1×
“[4] There are also notable racial and ethnic disparities in HCC, with a disproportionate burden of disease affecting American Indian, Hispanic, and Black persons more than non-Hispanic White persons.”
Asrani, S. K., Ghabril, M., Kuo, A., Merriman, R. B., Morgan, T. R. M., Parikh, N. D., Ovchinsky, N., Kanwal, F., Volk, M. L., Ho, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.32240 · Cited by 44
Self-citationPark, J. G., Park, S. Y., Tak, W. Y., Kweon, Y. O., Jang, S. Y., Lee, Y. R., Hur, K., Lee, H. J., & Lee, H. W. (2017) · Clinical Radiology · doi:10.1016/j.crad.2017.03.001 · Cited by 42 · cited 1×
“[276] As detailed above, the IMbrave 050 phase III RCT recently demonstrated superior recurrence-free survival using atezolizumab plus bevacizumab in the adjuvant setting for HCC patients at high-risk of recurrence after surgical resection or local ablation.”
Advance care planning (ACP) for specialists managing cirrhosis: A focus on patient‐centered care
Brisebois, A., Ismond, K. P., Carbonneau, M., Kowalczewski, J. A., & Tandon, P. (2017) · Hepatology · doi:10.1002/hep.29731 · Cited by 42 · cited 1×
“[338] Further, the treatment cascade for HCC is unpredictable and is governed by many things, including tumor biology and comorbidity, not to mention access and expertise.”
Short-term Outcomes of “Difficult” Laparoscopic Liver Resection at Specialized Centers
Ibuki, S., Hibi, T., Tanabe, M., Geller, D. A., Cherqui, D., & Wakabayashi, G. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004434 · Cited by 42
Singal, A. G., Reddy, S., Patel, H., Villarreal, D. L., Khan, A., Liu, Y., Cerda, V., Rich, N. E., Murphy, C. C., Tiro, J. A., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.014 · Cited by 42 · cited 1×
“[91,94,95] The AASLD recommends use of these evidence-based interventions to increase surveillance utilization in clinical practice.”
Self-citationKim, S. E., Lee, H. C., Shim, J. H., Park, H. J., Kim, K. M., Kim, P. N., Shin, Y. M., Yu, E. S., Chung, Y., & Suh, D. J. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02529.x · Cited by 41 · cited 1×
“[116] The probability of HCC and recommended management strategies differ by LI-RADS category (Figure 8).”
Basha, M. A. A., Sammak, D. A. E. A. E., & Sammak, A. A. E. (2017) · Clinical Radiology · doi:10.1016/j.crad.2017.05.019 · Cited by 40 · cited 1×
“…strongly associated with HCC. [113] LI-RADS criteria consider tumor size because accuracy for imaging techniques decreases in lesions 2 cm. [97,98,114] Therefore, for nodules ≥ 2 cm, APHE and one additional criteria (washout, enhancing capsule, or threshold growth) suffices for HCC diagnosis.”
Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations
Arvind, A., Joshi, S., Zaki, T. A., Burkholder, D. A., Parikh, N. D., Singal, A. G., Yekkaluri, S., Yokoo, T., Fetzer, D. T., Browning, T. G., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.042 · Cited by 39 · cited 1×
“[122,123] – 125] Among LR-M cases, rim APHE suggests non-HCC malignancy.”
Self-citationState‐Level HCC Incidence and Association With Obesity and Physical Activity in the United States
Lee, Y., Wang, J. J., Luu, M., Tseng, H., Rich, N. E., Lu, S. C.-L., Nissen, N. N., Noureddin, M., Singal, A. G., & Yang, J. D. (2021) · Hepatology · doi:10.1002/hep.31811 · Cited by 38
Self-citationAccuracy of the diagnostic evaluation of hepatocellular carcinoma with LI-RADS
Liu, W., Qin, J., Guo, R., Xie, S., Jiang, H., Wang, X., Kang, Z., Wang, J., & Shan, H. (2017) · Acta Radiologica · doi:10.1177/0284185117716700 · Cited by 36
Zhou, H., Zhang, C., Du, L.-Y., Jiang, J., Zhao, Q., Sun, J., Li, Q., Wan, M., Wang, X., Hou, X., et al. (2020) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-1168-6321 · Cited by 35 · cited 1×
“[110,111] CEUS can be used as a second-line modality in cases where MRI and CT are inconclusive, unavailable, or contraindicated, particularly when tumor biopsy is not feasible.”
Blüthner, E., Jara, M., Shrestha, R., Faber, W., Pratschke, J., Stockmann, M., & Malinowski, M. B. (2019) · HPB · doi:10.1016/j.hpb.2018.11.012 · Cited by 34 · cited 1×
“Of equal importance is an assessment of the anticipated future liver remnant (FLR) size, [166] underlying liver dysfunction, and presence of clinically significant portal hypertension (CSPH).”
Singal, A. G., Ghaziani, T., Mehta, N. J., Zhou, K., Grinspan, L. T., Benhammou, J. N., Moon, A. M., Yang, J. D., Salgia, R. J., Pillai, A. A., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000073 · Cited by 34 · cited 3×
“…HCC, suboptimal performance of CT or MRI to accurately diagnose HCC in lesions 1 cm, and expected tumor doubling time if the lesion were HCC. [87,97,98] If the liver lesion remains stable on two or more follow-up ultrasound exams, the risk of HCC is likely sufficiently low for the patient to…”
InfluentialSelf-citationKelley, R. K., Cheng, A., Braiteh, F. S., Park, J., Benzaghou, F., Milwee, S., Borgman, A. E., El-Khoueiry, A. B., Kayali, Z. K., Zhu, A. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps4157 · Cited by 33 · cited 1×
“[325] AASLD does not recommend lenvatinib plus pembrolizumab or cabo-zantinib plus atezolizumab as first-line therapies.”
Leal, C. R. G., Magalhães, C. R., Barbosa, D. S., Aquino, D., Carvalho, B., Balbi, E., Pacheco, L. C., Perez, R. D. M., Pinto, P. D. T. A., & Setúbal, S. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0621-x · Cited by 32
Frantz, S. K., Matsuoka, L. K., Vaheesan, K., Petroziello, M., Golzarian, J., Wang, E. W., Gandhi, R. T., Collins, Z. S., Brower, J. S., Rachakonda, V., et al. (2021) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2021.03.535 · Cited by 32
Self-citationMoctezuma‐Velázquez, C., Lewis, S. C., Lee, K., Amodeo, S., Llovet, J. M., Schwartz, M., Abraldeṣ, J. G., & Villanueva, A. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100364 · Cited by 31 · cited 1×
“In a study analyzing 280 patients with noncirrhotic HBV infection, the probability an LR-5 lesion was HCC was > 90% [115] in patients with HBV infection and PAGE-B score ≥ 10 (i.e., intermediate to high risk of HCC).”
Self-citationKanneganti, M., Marrero, J. A., Parikh, N. D., Kanwal, F., Yokoo, T., Mendiratta‐Lala, M., Rich, N. E., Gopal, P., & Singal, A. G. (2022) · Liver Transplantation · doi:10.1002/lt.26562 · Cited by 31
Self-citationNi, J.-Y., Fang, Z.-T., Sun, H., An, C., Huang, Z., Zhang, T.-Q., Jiang, X., Chen, Y.-T., Xu, L.-F., & Huang, J.-H. (2020) · European Radiology · doi:10.1007/s00330-019-06438-8 · Cited by 30
Chin, K. M., Prieto, M., Cheong, C., di Martino, M., Ielpo, B., Goh, B., & Koh, Y. (2021) · HPB · doi:10.1016/j.hpb.2021.01.009 · Cited by 30 · cited 1×
“…outcomes of curative therapy in NAFLD and non-NAFLD HCC reported improved disease-free and OS after liver resection in patients with NAFLD HCC. [161] Although there are significant limitations in these retrospective studies, including selection bias and heterogeneity in the populations,…”
Zhang, Y., Zhang, M., Chen, M., Mei, J., Xu, L., Guo, R., Lin, X., Li, J., & Peng, Z. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3213 · Cited by 29 · cited 1×
“[305] 308] Response evaluation criteria in solid tumors (RECIST) v1.”
Fujiwara, N., Kobayashi, M., Fobar, A. J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3760172 · Cited by 28
Nam, J. Y., Choe, A. R., Sinn, D. H., Lee, J., Kim, H. Y., Yu, S. J., Kim, Y. J., Yoon, J., Lee, J. M., Chung, J. W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06975-2 · Cited by 27 · cited 1×
“[147] – 292] Patients considered unsuitable for TACE may be better treated with systemic therapy, particularly considering improved responses and survival reported in the advanced-stage setting.”
Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma
Qadan, M., Fong, Z. V., Delman, A. M., Gabr, A., Salem, R., & Shah, S. A. (2021) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-05095-x · Cited by 26 · cited 1×
“[177] Other emerging methods to augment the FLR and allow surgical resection, such as associating liver partition and portal vein ligation for staged hepatectomy [178,179] and liver venous deprivation with portal vein and hepatic vein embolization, [180] are under investigation.”
Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk
Nasereldin, D. S., White, L. J., Hodge, D. O., Roberts, L. R., Patel, T. C., & Antwi, S. O. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.12.002 · Cited by 26
Length time bias in surveillance for hepatocellular carcinoma and how to avoid it
Cucchetti, A., Garuti, F., Pinna, A. D., Trevisani, F., & for the Italian Liver Cancer (ITA.LI.CA) group (2016) · Hepatology Research · doi:10.1111/hepr.12672 · Cited by 25 · cited 1×
“[60,61] The overall value of HCC surveillance programs must balance surveillance benefits against potential physical, financial, and psychological harms (Figure 4).”
Ye, S.-L., Chen, X., Yang, J., Bie, P., Zhang, S., Liu, F., Liu, L., Zhou, J., Dou, K., Hao, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6781 · Cited by 24
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Goh, M., & Sinn, D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0366 · Cited by 24
Honmyo, N., Kobayashi, T., Kuroda, S., Oshita, A., Onoe, T., Kohashi, T., Fukuda, S., Ohmori, I., Abe, T., Imaoka, Y., et al. (2020) · HPB · doi:10.1016/j.hpb.2020.05.008 · Cited by 23 · cited 1×
“From an oncologic perspective, tumor number, [162,163] anatomic location, presence of vascular invasion, and planned extent of hepatectomy [164,165] are important determinants of feasibility for surgical resection.”
Radiation-induced liver disease in the era of SBRT: a review
de la Pinta, C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1814744 · Cited by 22 · cited 1×
“[277] EBRT has mostly been studied in single-arm studies.”
Preoperative Portal Vein Embolization for Liver Resection: An updated meta-analysis
Huang, Y., Ge, W., Kong, Y., Ding, Y., Gao, B., Qian, X., & Wang, W. (2021) · Journal of Cancer · doi:10.7150/jca.50371 · Cited by 22 · cited 1×
“[174] Transarterial radioembolization (TARE) with Yttrium-90 has recently been established as an acceptable treatment for solitary unresectable HCC, [175] and there are increasing data for its utilization to enhance FLR [176] and allow for surgical resection.”
Niu, Y., Fan, S., Luo, Q., Chen, L., Huang, D., Chang, W., Qin, W., & Shi, G. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00036 · Cited by 21
Cacciaguerra, A. B., Görgeç, B., Lanari, J., Cipriani, F., Russolillo, N., Mocchegiani, F., Zimmitti, G., Alseidi, A. A., Ruzzenente, A., Edwin, B., et al. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1087 · Cited by 20 · cited 1×
“[184] Thus, MIS approaches may extend resectability criteria, allowing patients with mild portal hypertension to safely undergo minor liver resection (Figure 10).”
Li, S., Zhou, L., Chen, R., Chen, Y., Niu, Z., Qian, L., Fang, Y., Xu, L., Xu, H., & Zhang, L. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.10.009 · Cited by 19 · cited 1×
“[108,109] However, compared to CT and MRI, CEUS has limitations of operator dependency, impact of patient/tumor factors on visualization (similar to ultrasound), lack of full staging data, and insufficient information for treatment planning.”
Shin, J., Lee, S., Hwang, J. A., Lee, J. E., Chung, Y. E., Choi, J., & Park, M. (2022) · European Radiology · doi:10.1007/s00330-021-08382-y · Cited by 19 · cited 1×
“[124] Therefore, biopsy should be performed for patients with LR-M observations.”
National experience with living donor liver transplantation for hepatocellular carcinoma
Silverstein, J. F., Yao, F. Y., Grab, J. D., Braun, H. J., Roberts, J. P., Dodge, J. L., & Mehta, N. J. (2022) · Liver Transplantation · doi:10.1002/lt.26439 · Cited by 17 · cited 1×
“…increasing in the United States, with a recent analysis of OPTN data demonstrating excellent post-LT survival in the setting of LDLT for HCC. [ 227,228 ] Use of bridging therapy Given the mandatory 6-month wait time prior to the awarding of MELD exception, neoadjuvant locoregional therapy (LRT)…”
Self-citationIs bone scintigraphy indicated in surgical work-up for hepatocellular carcinoma patients?
Witjes, C. D. M., Verhoef, C. K., Kwekkeboom, D. J., Dwarkasing, R. S., de Man, R. A., & IJzermans, J. N. M. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.07.013 · Cited by 16 · cited 1×
“[146] AASLD advises review of staging imaging studies by a multidisciplinary tumor board with an expert diagnostic radiologist ( see Multidisciplinary Care ).”
The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma
Yao, F. Y., Fidelman, N. A., & Mehta, N. J. (2021) · Seminars in Liver Disease · doi:10.1055/s-0040-1716565 · Cited by 16 · cited 1×
“[242] As noted above, patients with HCC meeting UNOS-DS criteria who are successfully downstaged to Milan criteria are eligible to receive automatic MELD exception after a period of observation (Table 4).”
Self-citationClinical Outcomes of Patients With Suspicious (LI-RADS 4) Liver Observations
Onyirioha, K., Joshi, S., Burkholder, D. A., Yekkaluri, S., Parikh, N. D., Singal, A. G., Wolf, E., Yokoo, T., Browning, T. G., Mendiratta‐Lala, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.03.038 · Cited by 16 · cited 1×
“[120,121] Given several factors that should be considered in these circumstances, AASLD advises multidisciplinary discussion to determine optimal follow-up for patients with LR-4 observations.”
Self-citationLifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma
Simon, T. G., & Chan, A. T. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.06.002 · Cited by 15 · cited 1×
“[45,46] Although supporting data for aspirin, statins, and metformin are similar to that of coffee — that is, observational data with risk of confounding — these medications have higher potential risks of toxicity and adverse events (AEs).”
Yokoo, T., Singal, A. G., de Leon, A. D., Ananthakrishnan, L., Fetzer, D. T., Pedrosa, I., & Khatri, G. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-02133-w · Cited by 14 · cited 1×
“[86] Ongoing studies may clarify the most appropriate niche for cost-effective and safe use of CT-or MRI-based surveillance, perhaps in patients in whom ultrasound performs least reliably, such as those with truncal obesity or marked parenchymal heterogeneity.”
Self-citationArif, D., Mettler, T. N., & Adeyi, O. A. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.12.002 · Cited by 14 · cited 1×
“[139] Given insufficient accuracy, AFP is no longer recommended for HCC diagnosis.”
Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma
Simon, T. G., Kim, M. N., Luo, X., Liu, X., Yang, W., Ma, Y., Chong, D. Q., Fuchs, C. S., Stampfer, M. J., Giovannucci, E. L., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0549 · Cited by 14
Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma
Shioga, T., Kondo, R., Ogasawara, S., Akiba, J., Mizuochi, S., Kusano, H., Mihara, Y., Tanigawa, M., Kinjo, Y., Naito, Y., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14409 · Cited by 12 · cited 1×
“[ 133,134 ] 137] A negative biopsy does not eliminate the possibility of HCC, and a second biopsy is recommended when findings are inconclusive, particularly if tumor growth or change in enhancement pattern are identified during follow-up but the lesion is still not categorized as LR-5.”
Fu, R., Qiu, T., Ling, W., Lu, Q., & Luo, Y. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01727-3 · Cited by 11 · cited 1×
“Other measures including the MELD score or MELD including sodium (MELD-Na), ALBI score, [171] indocyanine green kinetics, [172] and liver stiffness measurement by transient elastography [173] are associated with risk of postresection hepatic decompensation and may also be used to refine patient…”
Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough?
Mirdad, R. S., Hyer, J. M., Díaz, A., Tsilimigras, D. I., Azap, R. A., Paro, A., & Pawlik, T. M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26433 · Cited by 9 · cited 1×
“[197] There is a need for effective (neo)adjuvant therapy to reduce risk of HCC recurrence after surgical resection.”
Heredia, N. I., Gaba, R., Liu, Y., Jain, S., Rungta, M., Rungta, M., El‐Serag, H. B., Kanwal, F., Thrift, A. P., & Balakrishnan, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-09583-1 · Cited by 9 · cited 1×
“[22] 26 – 28] In the United States, state-level HCC incidence has a moderate correlation with regional obesity and lack of physical activity, suggesting a possible benefit of public policy interventions.”
Aoki, T., Kubota, K., Matsumoto, T., Nitta, H., Otsuka, Y., Wakabayashi, G., Kaneko, H., & the Endoscopic Liver Surgery Study Group of Japan (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.917 · Cited by 7 · cited 1×
“…in well-selected patients with HCC. [181] Although many centers commonly perform limited minor resections in anatomically favorable locations (Segments 2, 3, 5, and 6) using MIS techniques, [182] major hepatectomy via an MIS approach should only be performed in high-volume, experienced centers.”
Bai, Y.-N., Lian, Y., Chen, X., Wu, J.-Y., Lai, J.-L., Qiu, F., Zhou, S.-Q., Zhu, Z.-J., Tian, Y.-F., Wang, Y.-D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.616263 · Cited by 3 · cited 1×
“[ 133,134 ] 137] A negative biopsy does not eliminate the possibility of HCC, and a second biopsy is recommended when findings are inconclusive, particularly if tumor growth or change in enhancement pattern are identified during follow-up but the lesion is still not categorized as LR-5.”
Research works printed but not linked: 2
- Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
- Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057
Cited by
Sorted by citations
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 1,029
Self-citationEASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P. T. F., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Wong, G. L., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 480
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00469-2 · Cited by 469
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationSangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.02.005 · Cited by 365
Self-citation
Metadata
- Authors
- Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- University Health Network (CA)
- Oregon Health & Science University (US)
- Northwestern Medical Faculty Foundation (US)
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Vanderbilt University Medical Center (US)
- Medical College of Wisconsin (US)
- Stanford Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Corresponding author
- Singal, Amit G.
- ORCID
- Venue
- Hepatology
- Published
- 2023-05-22
- Volume
- 78
- Issue
- 6
- Pages
- 1922-1965
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10663390
- OpenAlex
- W4377011124
- Cited by
- 2,052
- References
- 341
- Citations by year
- 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
- FWCI
- 346.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Boston Scientific Corporation
- Exelixis
- Incyte
- Cancer Research UK (26813)
- Eisai
- Ipsen
- Sirtex Medical
- National Institutes of Health (UL1TR001863)
- Genentech
- National Cancer Institute (P50CA062924, R01CA285544)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
- MeSH terms
- Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
